Search Results - "Attili, I"

Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials by Attili, I., Passaro, A., de Marinis, F.

Get full text

Testing for COVID-19 in lung cancer patients by Passaro, A., Peters, S., Mok, T.S.K., Attili, I., Mitsudomi, T., de Marinis, F.

Get full text

Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges by Pavan, A, Attili, I, Pasello, G, Guarneri, V, Conte, P F, Bonanno, L

“…Management of small cell lung cancer (SCLC) has not changed over the last decades. In more recent years, alterations of DNA repair machinery and other…”
Get full text

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes by Bonanno, L., Pavan, A., Dieci, M.V., Di Liso, E., Schiavon, M., Comacchio, G., Attili, I., Pasello, G., Calabrese, F., Rea, F., Favaretto, A., Rugge, M., Guarneri, V., Fassan, M., Conte, P.F.

“…The prognosis of small-cell lung cancer (SCLC) is dismal and new effective therapies are needed. Immunotherapy looks promising, but no molecular predictive…”
Get full text

Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT) by Gridelli, C., Peters, S., Velcheti, V., Attili, I., de Marinis, F.

“…The use of immune checkpoint inhibitors (ICIs) in the front-line treatment of advanced non-small-cell lung cancer (NSCLC) is currently the standard of care…”
Get full text

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology by Gridelli, C., Peters, S., Mok, T., Forde, P.M., Reck, M., Attili, I., de Marinis, F.

“…Immunotherapy represents the standard of care in the first-line treatment of advanced non-small-cell lung cancer (NSCLC), either as monotherapy in high…”
Get full text

Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse by Pavan, A., Calvetti, L., Dal Maso, A., Attili, I., Pasello, G., Aprile, G., Guarneri, V., Conte, P., Bonanno, L.

Get full text

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers by Spitaleri, G., Trillo Aliaga, P., Catania, C., Signore, E. Del, Attili, I., Santoro, C., Giugliano, F., Berton Giachetti, P.P.M, Curigliano, G., Passaro, A., de Marinis, F.

“…•Pivotal trials of COVID-19 vaccines did not include cancer patients, with questions remaining about their safety and efficacy in this population•In this…”
Get full text

Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy by Bonanno, L., Zulato, E., Attili, I., Pavan, A., Del Bianco, P., Nardo, G., Boscolo Bragadin, A., Pasqualini, L., Calabrese, F., Fassan, M., Pasello, G., Guarneri, V., Amadori, A., Conte, P., Indraccolo, S.

Get full text

Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study by Bonanno, L., Zulato, E., Attili, I., Pavan, A., Del Bianco, P., Nardo, G., Verza, M., Pasqualini, L., Pasello, G., Zago, G., Frega, S., Fassan, M., Calabrese, F., Amadori, A., Guarneri, V., Conte, P.F., Indraccolo, S.

Get full text

Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study by Frega, S., Macerelli, M., Del Conte, A., Bonanno, L., Bartoletti, M., Polo, V., Zago, G., Follador, A., Attili, I., Pavan, A., Urso, L., Basso, S.M.M., Fasola, G., Conte, P., Pasello, G.

Get full text

Surgery in multimodal management in non-metastatic small cell lung cancer: a retrospective monocentric series by Di Liso, E., Pavan, A., Schiavon, M., Gregori, D., Comacchio, G., Attili, I., Mantiero, M., Pasello, G., Zago, G., Polo, V., Frega, S., Milite, N., Rea, F., Conte, P., Bonanno, L.

Get full text

42P Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low by Attili, I., Valenza, C., Santoro, C., Antonarelli, G., Trillo Aliaga, P., Del Signore, E., Catania, C., Spitaleri, G., Passaro, A., de Marinis, F.

Get full text

129P Association of clinico-pathological markers with longitudinal liquid biopsy (LB) results predicts outcome in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs) by Bonanno, L., Zulato, E., Del Bianco, P., Boscolo Bragadin, A., Attili, I., Pavan, A., Nardo, G., Dal Maso, A., Ferro, A., Frega, S., Pasello, G., M. Fassan, Calabrese, F., Guarneri, V., Indraccolo, S.

Get full text

1124P Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP) by Passaro, A., Lo Russo, G., Passiglia, F., D'Arcangelo, M., Sbrana, A., Russano, M., Bonanno, L., Giusti, R., Metro, G., Bertolini, F., Grisanti, S., Carta, A., Cecere, F.L., Montrone, M., Massa, G., Attili, I., de Marinis, F.

Get full text

1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial by Cappuzzo, F., Delmonte, A., Landi, L., Andrikou, K., Dal Maso, A., Minuti, G., Lee, C., Wang, X., Papi, M., Metro, G., Attili, I., Piantedosi, F.V., Pilotto, S., Gori, S., Rossi, G., Buglioni, S., Giannarelli, D., Bonanno, L.

Get full text

1939P Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs) by Bonanno, L., Zulato, E., Attili, I., Nardo, G., Pavan, A., Paola, D.B., Boscolo Bragadin, A., Pasello, G., Guarneri, V., Conte, P.F., Indraccolo, S.

Get full text

158PImmune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse by Pavan, A, Calvetti, L, Dal Maso, A, Attili, I, Pasello, G, Aprile, G, Guarneri, V, Conte, P, Bonanno, L

Get full text

1967P - Triple MET/SRC/PIM inhibition in MET addicted tumors by Attili, I., Bonanno, L., Bracht, J.P., Berenguer, J., Codony-Servat, C., Codony-Servat, J., Ito, M., Conte, P.F., Cui, J.J., Karachaliou, N., Rosell, R.

“…MET addicted tumors are known to show very short response to single MET inhibition. In MET addicted cells, MET inhibition leads to activation of proviral…”
Get full text

1967PTriple MET/SRC/PIM inhibition in MET addicted tumors by Attili, I, Bonanno, L, Bracht, J P, Berenguer, J, Codony-Servat, C, Codony-Servat, J, Ito, M, Conte, P F, Cui, J J, Karachaliou, N, Rosell, R

“…Abstract Background MET addicted tumors are known to show very short response to single MET inhibition. In MET addicted cells, MET inhibition leads to…”
Get full text